Hansa Biopharma AB (publ) (24H.F)

2.4800 -0.0960 (-3.73%) As of 09:09AM CEST. Market open.

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 166

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Søren Tulstrup M.Sc	President & CEO	16.12M	N/A	1965
Mr. C. Evan Ballantyne	Chief Financial Officer	N/A	N/A	1960
Dr. Christian Kjellman	Senior VP & COO	N/A	N/A	1967
Dr. Hitto Kaufmann Ph.D.	Chief Scientific Officer	N/A	N/A	1971
Ms. Eva-Maria Joed	Vice President of Finance & Administration	N/A	N/A	1969
Mr. Klaus Sindahl	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Anne Säfström Lanner	Senior VP & Chief Human Resources Officer	N/A	N/A	1969
Mr. Emanuel Björne	VP & Head of Business Development	N/A	N/A	1973
Dr. Lena Winstedt	Head of Science	N/A	N/A	1969
Ms. Vincenza Nigro M.B.A.	VP & Head of Medical Affairs	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Corporate Governance

Hansa Biopharma AB (publ)’s ISS Governance QualityScore as of May 1, 2024 is 1. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.